DNMT3B and breast cancer: Consistent with the role of miR-29s in cancer, their targets DNMT3A and DNMT3B have been described as overexpressed in various neoplasms and associated with poor prognosis in numerous tumors, including BC [32,33,51,57,58,59,60].